Drug evaluation: AMG-531 for the treatment of thrombocytopenias.
Amgen Inc is developing AMG-531, a peptibody that binds to the thrombopoietin receptor Mpl, for the potential treatment of immune thrombocytopenic purpura (ITP), chemotherapy-induced thrombocytopenia (CIT) and thrombocytopenia in myelodysplastic syndrome (MDS). Results of the US phase III trial in ITP are expected to be available in the second half of 2006, while a phase II trial in CIT is still underway. A Japanese phase II ITP study has been initiated, as has a phase II trial of MDS patients in the US and France.
Rice
Lawrence
L
Baylor College of Medicine, Houston, TX 77030, USA. lrice@bcm.tmc.edu
D000818:Animals; D002352:Carrier Proteins / Q000009:adverse effects* / Q000138:chemical synthesis / Q000378:metabolism / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*; D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D006801:Humans; D021281:Quantitative Structure-Activity Relationship; D011961:Receptors, Fc / Q000378:metabolism / Q000627:therapeutic use*; D011993:Recombinant Fusion Proteins; D013921:Thrombocytopenia / Q000188:drug therapy*; D013926:Thrombopoietin
D002352:Carrier Proteins; D011961:Receptors, Fc; D011993:Recombinant Fusion Proteins; D013926:Thrombopoietin; C488777:romiplostim